Brokerages Set Abeona Therapeutics Inc. (NASDAQ:ABEO) Target Price at $19.40

Abeona Therapeutics Inc. (NASDAQ:ABEO) has been assigned an average recommendation of “Buy” from the eight brokerages that are presently covering the firm, Marketbeat reports. Eight investment analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $18.33.

Several brokerages have issued reports on ABEO. BidaskClub downgraded shares of Abeona Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday. HC Wainwright set a $20.00 price objective on shares of Abeona Therapeutics and gave the company a “buy” rating in a research report on Wednesday, July 19th. Cantor Fitzgerald set a $21.00 price objective on shares of Abeona Therapeutics and gave the company a “buy” rating in a research report on Tuesday, July 18th. Maxim Group reaffirmed a “buy” rating and issued a $17.00 price objective (up previously from $14.00) on shares of Abeona Therapeutics in a research report on Tuesday, July 18th. Finally, Zacks Investment Research raised shares of Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a research report on Tuesday, July 11th.

COPYRIGHT VIOLATION WARNING: “Brokerages Set Abeona Therapeutics Inc. (NASDAQ:ABEO) Target Price at $19.40” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.chaffeybreeze.com/2017/07/29/analysts-set-abeona-therapeutics-inc-nasdaqabeo-target-price-at-19-40-updated-updated-updated.html.

Several institutional investors have recently added to or reduced their stakes in ABEO. Family Management Corp acquired a new position in Abeona Therapeutics during the first quarter valued at approximately $120,000. Highbridge Capital Management LLC boosted its position in Abeona Therapeutics by 23.5% in the first quarter. Highbridge Capital Management LLC now owns 681,611 shares of the biopharmaceutical company’s stock valued at $3,408,000 after buying an additional 129,811 shares during the period. Geode Capital Management LLC boosted its position in Abeona Therapeutics by 2.4% in the first quarter. Geode Capital Management LLC now owns 196,073 shares of the biopharmaceutical company’s stock valued at $980,000 after buying an additional 4,588 shares during the period. Segantii Capital Management Ltd boosted its position in Abeona Therapeutics by 564.6% in the first quarter. Segantii Capital Management Ltd now owns 33,894 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 28,794 shares during the period. Finally, Laurion Capital Management LP acquired a new position in Abeona Therapeutics during the first quarter valued at approximately $277,000. Institutional investors own 35.64% of the company’s stock.

Shares of Abeona Therapeutics (NASDAQ:ABEO) opened at 8.75 on Friday. Abeona Therapeutics has a one year low of $2.70 and a one year high of $10.26. The stock’s market capitalization is $352.23 million. The company’s 50-day moving average is $7.25 and its 200-day moving average is $5.78.

Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Thursday, May 18th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.02. The firm had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.28 million. Abeona Therapeutics had a negative net margin of 2,568.57% and a negative return on equity of 26.99%. On average, equities research analysts anticipate that Abeona Therapeutics will post ($0.57) earnings per share for the current year.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply